Search

As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team. [ABSTRACT FROM AUTHOR]

The layoffs are accompanied by leadership changes, a prioritized preclinical portfolio and a shift of resources toward external opportunities. [ABSTRACT FROM AUTHOR]

As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team. [ABSTRACT FROM AUTHOR]

As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team. [ABSTRACT FROM AUTHOR]

IGM, Y-mAbs, Passage Bio and Shoreline Biosciences have each revealed plans to cut jobs as they rework their pipelines and business structures. [ABSTRACT FROM AUTHOR]

As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team. [ABSTRACT FROM AUTHOR]

4DMT is axing two clinical programs and shutting off funds for three other assets, with resources to be pivoted toward gene therapy 4D-150. [ABSTRACT FROM AUTHOR]

The cuts are likely a lagging indicator of market health, Roivant CEO Matt Gline told Fierce Biotech. [ABSTRACT FROM AUTHOR]

As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team and let us know. [ABSTRACT FROM AUTHOR]

The firm aims to "reduce operational complexities and simplify select workflows" in order to become more agile. [ABSTRACT FROM AUTHOR]

As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team and let us know. [ABSTRACT FROM AUTHOR]

As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team and let us know. [ABSTRACT FROM AUTHOR]

Editas is laying off three-quarters of its workforce after the gene editing biotech was unable to find a partner for its sickle cell disease med. [ABSTRACT FROM AUTHOR]

The company framed the changes as a return to "its founding TechBio mission" after years in which it aspired to be a fully fledged biotech. [ABSTRACT FROM AUTHOR]

As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team and let us know. [ABSTRACT FROM AUTHOR]

Belharra Therapeutics has come down from its surfing high, implementing a workforce reduction that will impact 21 people. [ABSTRACT FROM AUTHOR]

Cancer-focused Alligator Bioscience is clamping down on costs, laying off 70% of its team in efforts to save around $6 million every year. [ABSTRACT FROM AUTHOR]

On the heels Kronos Bio's decision to can its last remaining clinical asset earlier this month, the company said it would roll out "significant expense reduction strategies" to buy itself more time [ABSTRACT FROM AUTHOR]

Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now discontinuing its patch pump program as part of a broader restructuring and layoffs. [ABSTRACT FROM AUTHOR]

Medigene will slim its head count by 40% and pause plans to get its first asset into the clinic in order to channel cash to its T cell receptor-guided therapies. [ABSTRACT FROM AUTHOR]

In another sign of biopharma's waning interest in the traditional ex vivo gene therapy approach, CSL Behring is shutti [ABSTRACT FROM AUTHOR]

Amid a reorganization campaign that's breathed new life into hybrid generic and innovative medicines player Teva, the company is leaning into novel medicines and formulations more than ever and ado [ABSTRACT FROM AUTHOR]

The recent decision to merge Genentech's two cancer departments was made for "scientific reasons," according to executives. [ABSTRACT FROM AUTHOR]

As August begins, UniQure, HilleVax and Arbutus have all left staff behind. [ABSTRACT FROM AUTHOR]

Immunology biotech VBI Vaccines plans to file for bankruptcy and sell off its assets. [ABSTRACT FROM AUTHOR]

CureVac shared news of the deal alongside a restructuring that will put 30% of its employees out of work and extend its cash runway into 2028. [ABSTRACT FROM AUTHOR]

Barinthus used positive data from a pair of phase 2 trials for its hepatitis B therapy as justification for jettisoning a quarter of its workforce. [ABSTRACT FROM AUTHOR]

Ikena Oncology is again shrinking its herd and signaling a tough fight ahead as one of two assets, a TEAD1-selective Hippo pathway inhibitor, is cut. [ABSTRACT FROM AUTHOR]

This paper analyzes the different opportunities for venture capital in the field of business restructuring in a post-pandemic scenario. Specifically, it will address investment options in companies in which venture capital funds are already partners, as well as opportunities to participate in the restructuring of new businesses and to make such investments profitable through the instrument of credit capitalization. Additionally, the role of the venture capital funds in the face of the new Directive on preventive restructuring frameworks will be discussed. [ABSTRACT FROM AUTHOR]

Bristol Myers Squibb is closing a 256,000 square-foot research facility in Redwood City, CA as part of the company's larger restructuring. [ABSTRACT FROM AUTHOR]

Bristol Myers' $1.5 billion cost-cutting plan comes after the company spent $18.1 billion on two large acquisitions since December 2023. [ABSTRACT FROM AUTHOR]

Sanofi is cutting more than 60 employees in Ghent with more on the chopping block at the company's Belgium HQ in Diegem. [ABSTRACT FROM AUTHOR]

Sanofi is laying off staff around the globe following a 'full pipeline reprioritization,' according to an email from R&D chief Houman Ashrafian [ABSTRACT FROM AUTHOR]

Chief Commercial Officer Robert Francomano will be departing along with General Counsel and Corporate Secretary Barbara Wood. [ABSTRACT FROM AUTHOR]

After a strategic review, small oncology biotech Kineta is conducting a corporate restructuring and reducing its workforce by 64%. [ABSTRACT FROM AUTHOR]

In addition to other inventory reduction initiatives, the moves are expected to cost between $125 million and $150 million through the end of 2025. [ABSTRACT FROM AUTHOR]

After losing a patent infringement lawsuit last year that ended with an order to pay $31 million in damages, NanoString is plotting a new way forward. [ABSTRACT FROM AUTHOR]

After inking a $75 million deal to acquire Vyrsa Technologies late last year, Nevro now appears to be trying to lessen the impact of those costs. [ABSTRACT FROM AUTHOR]

The fate of Hepion's phase 2b NASH trial hangs in the balance as the biotech's CEO hits the exit and the company cuts costs by 60%. [ABSTRACT FROM AUTHOR]

As it awaits regulatory clearance for its TTFields technology in NSCLC, Novocure is narrowing its pipeline and its workforce to conserve funds. [ABSTRACT FROM AUTHOR]

Candel Therapeutics is taking difficult measures to keep its clinical flame burning, laying off 50% of its team as part of a wide scale restructuring. [ABSTRACT FROM AUTHOR]

Acutus Medical is planning to cut a majority of its jobs as it narrows its focus to only the most potentially profitable pursuits. [ABSTRACT FROM AUTHOR]

A year after Lyell Immunopharma lost a $1 billion biobucks partnership with GSK, the cell therapy biotech is offloading a quarter of its staff. [ABSTRACT FROM AUTHOR]

After securing an approval for a microbiome therapy, Seres is facing some tough choices, resulting in a restructuring that will claim 41% of staff. [ABSTRACT FROM AUTHOR]

After achieving a positive outcome in a preliminary look at a phase 1/2 trial for a solid tumor candidate, Kronos is restructuring and cutting staff. [ABSTRACT FROM AUTHOR]

As it continues to take advantage of the hole left in the CPAP market by Philips' ongoing recall, ResMed is still fine-tuning its long-term growth strategy—a process that's now resulting in short-term shrinkage. [ABSTRACT FROM AUTHOR]

With a cash runway that could run out of tarmac in six months, British biotech Freeline is considering a buyout from its majority shareholder Syncona. [ABSTRACT FROM AUTHOR]

Rite Aid filed for bankruptcy protection Sunday in an effort to address lawsuits over its alleged role in the opioid epidemic and mounting debt. [ABSTRACT FROM AUTHOR]

Johnson & Johnson MedTech expects to take a $250 million revenue hit before 2026 as it restructures its orthopedics businesses and exits low-performing markets. [ABSTRACT FROM AUTHOR]

The cell engineering biotech is pulling back from in vivo delivery and reducing its head count by 29% to stretch its cash runway deeper into 2025. [ABSTRACT FROM AUTHOR]